The Synairgen (SNG) share price tanks 20% on earnings. What happened?

The Synairgen (LON:SNG) share price dropped by double-digits, despite the firm making key progress in clinical trials. Is this a buying opportunity?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The Synairgen (LSE:SNG) share price took quite a hit last week following its latest earnings report. The stock is down around 21% since last Thursday. And this recent decline has pushed its 12-month performance to a disappointing -17% return. Is this business in trouble? Or is this volatility an opportunity to grab some shares at a discount? Let’s take a closer look.

The progress continues

Despite what the SNG share price would suggest, Synairgen has actually achieved some promising milestones. Its flagship drug SNG001 is currently undergoing phase three trials. And the last patient is on track to be enrolled by the end of November.

As a reminder, SNG001 is an inhaled interferon beta formulation to treat severe respiratory diseases. That’s a fancy way of saying, patients aren’t injected but rather breathe the drug directly into their lungs. The company is currently running trials to verify its effectiveness against severe cases of Covid-19.

Early lab results released back in May showed the treatment successfully eliminated the virus to undetectable levels. And if a similar outcome can be replicated in the upcoming phase three trials, Synairgen might soon shed its pre-revenue status. The next set of results for SNG001 are expected to arrive within the next few months. In the meantime, the firm has already begun exploring its effectiveness on other Covid-19 variants. And recruitment for its phase two trial of home treatment has just finished recruiting.

Needless to say, this is quite an encouraging amount of progress over the last six months. So why did the share price fall on the news?

The Synairgen SNG share price has its risks

The crashing share price

Drug development is a very expensive endeavour, with no guarantee of results. Now that SNG001 is entering phase three trials, the costs are ramping up. Consequently, research & development expenses have exploded over the last six months from £4.5m in 2020 to £36.9m in 2021. And with more staff on the payroll, administrative costs have more than doubled.

In my experience, seeing a high ramp-up of costs when entering phase three trials is not uncommon. The study is estimated to have a total of 610 patients in 99 different hospitals around the world. And hospital fees for running clinical trials are high.

Consequently, ignoring the effects of taxes, the firm reported a loss of £38.9m. That’s more than 600% larger than a year ago. So I can see why some investors were spooked, triggering the fall of the SNG share price.

The bottom line

The spike in costs ultimately doesn’t concern me as much as it does the market. After all, Synairgen still has £46.2m of cash on its balance sheet, which is a decent liquidity level. However, given the amount of capital being sunk into this single product, it does mean the SNG share price is exposed to a single-asset risk.

Suppose these trials don’t produce positive results? In that case, the SNG share price could be on the verge of collapsing even further. Personally, this binary outcome doesn’t tempt me. Therefore, I’m still keeping Synairgen on my watchlist for now.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Zaven Boyrazian has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Top Stocks

5 stocks Fools have bought for growth and dividends

Sometimes, an investor doesn't have to make the choice between buying a growth stock or dividend shares! Some investments offer…

Read more »

New year resolutions 2025 on desk. 2025 resolutions list with notebook, coffee cup on table.
Investing Articles

1 investment I’m eyeing for my Stocks and Shares ISA in 2025

Bunzl is trading at a P/E ratio of 22 with revenues set to decline year-on-year. So why is Stephen Wright…

Read more »

The flag of the United States of America flying in front of the Capitol building
Investing Articles

Where will the S&P 500 go in 2025?

The world's biggest economy and the S&P 500 index have been flying this year. Paul Summers ponders whether there are…

Read more »

Passive income text with pin graph chart on business table
Dividend Shares

How to invest £20,000 in 2025 to generate safe passive income

It’s easy to generate passive income from the stock market today. Here’s how Edward Sheldon thinks investors should build an…

Read more »

Runner standing at the starting point with 2025 year for starting in new year 2025 to achieve business planing and success concept.
Investing Articles

Could the FTSE 100 hit 9,000 in 2025?

The FTSE 100 has lagged other indexes over the last year. But some commentators believe 2025 could be a stellar…

Read more »

Investing Articles

Why selling cars could drive the Amazon share price higher in 2025

After outperforming the S&P 500 in 2024, Stephen Wright's looking at what could push the Amazon share price to greater…

Read more »

Pink 3D image of the numbers '2025' growing in size
Investing Articles

3 of the best British shares to consider buying for 2025

Looking for UK shares to think about buying next year? These three stocks have all been brilliant long-term investments but…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

5 crucial Warren Buffett investing habits and a stock to consider buying now

Here's a UK stock idea that looks like it's offering the kind of good value sought by US billionaire investor…

Read more »